Reasons for discontinuation of depot medroxyprogesterone acetate

International Congress Series

Volumn 1271, Issue C, 2004, Pages 315-318

  Hajikazemi, Eftekharalsadat ^a   Nikpour, Soghra ^a   Haghani, Hamid ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Depot medroxyprogesterone acetate; Discontinuation

Indexed keywords

EID: 84904268084     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.05.067     Document Type: Article

References (10)

1. World Health organization, Biennial report reproductive research, Geneva, 2000.
2. Potter, L.S., et al. Depot medroxyprogesterone acetate pioneers. Contraception 56 (1997), 305–312.
3. Chilvers, C.E., Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge. Drug Safety 15:3 (1996), 212–218.
4. C.H. Paul, D. Skegg, S.H. Williamas, Depot medroxyprogesterone acetate patterns of use and reason for discontinuation of contraception 56 (4) (1997) 209-214.
5. E.M. Belsey, Task force on long acting systemic agents for fertility regulation, World Health Organization Special Program of Research Development and Research Training. Menstrual bleeding patterns in untreated women and with long acting method of contraception 7 (1991) 247-270.
6. Polaneczky, M., et al. Early experience with the contraceptive use of Depot medroxyprogesterone acetate in an inner city clinic population. Fam. Plann. Perspect 28:4 (1996), 174–178.
7. Nickols, F.R., Zwelling, E.L., Maternal Newborn Nursing. 2nd ed., 1997, Sunders, USA.
8. Cunningham, M., Williams Obstetrics. 20th ed., 1997, Simon & Schuster, USA.
9. Kaunitz, A.M., Injectable Depot medroxyprogesterone acetate contraception. Int. J. Fert. Women's Med 43:2 (1998), 73–83.
10. Kipersztok, S., The new progestins. Infertil. Reprod. Med. Clin. North Am 6:1 (1995), 61–75.